Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotatercept - Merck & Co

Next Previous
Drug Profile

Sotatercept - Merck & Co

Alternative Names: ACE-011; ACTRIIA-Fc - Merck & Co; MK-7962; Sotatercept-csrk - Merck & Co; WINREVAIR

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation; Indiana University; Merck & Co; University of Texas M. D. Anderson Cancer Center
  • Class Antianaemics; Antihypertensives; Antineoplastics; Immunoglobulin Fc fragments; Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Pulmonary arterial hypertension
  • Phase II Pulmonary hypertension
  • Discontinued Anaemia; Beta-thalassaemia; Bone metastases; Chemotherapy-induced anaemia; Diamond-Blackfan syndrome; Myelodysplastic syndromes; Myelofibrosis; Postmenopausal osteoporosis; Renal osteodystrophy; Sickle cell anaemia; Vascular calcification

Most Recent Events

  • 26 Mar 2024 Merck & Co intends to launch sotatercept for Pulmonary arterial hypertension in the US (SC) in April 2024
  • 26 Mar 2024 Efficacy data from a phase III STELLAR trial in Pulmonary artificial hypertension released by Merck
  • 20 Nov 2023 Efficacy and adverse events data from a phase III SOTERIA trial for Pulmonary arterial hypertension presented at the 33rd Annual Congress of the European Respiratory Society (ACEPS-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top